要文快报！赢家时尚(03709)回购股份 彰显发展信心

赢家时尚(03709)回购股份 彰显发展信心

香港，2024年6月18日 - 赢家时尚（03709）今日宣布，公司根据股份奖励计划的条款及条件，其受托人于2024年6月14日从市场回购合共4.65万股公司股份，每股股份平均价格约为10.49港元。此次回购股份将用于奖励公司员工，以激励他们为公司创造更大价值。

赢家时尚近年来业绩表现稳健，2023年营业额同比增长10.5%，净利润同比增长12.8%。公司积极拓展海外市场，并加大对数字化技术的投入，为未来发展奠定了坚实基础。

此次股份回购是公司管理层对公司未来发展前景充满信心的体现，也是公司长期激励机制的重要组成部分。回购股份将有助于提升公司每股收益，增强股东回报，并进一步凝聚员工力量，推动公司高质量发展。

分析人士认为，赢家时尚此次回购股份具有以下积极意义：

• 体现公司管理层对公司发展前景的信心；
• 增强公司股权结构的稳定性；
• 提升公司每股收益和股东回报；
• 激励员工，凝聚公司力量。

赢家时尚表示，公司将继续坚持以客户为中心，以创新为驱动，致力于为股东创造更大的价值。

此外， 赢家时尚还宣布，公司将于近期召开股东大会，审议公司2023年年度报告以及其他相关事项。

相关背景：

• 赢家时尚是一家主要从事服装设计、生产和销售的港资企业，公司产品包括女装、男装、童装等。
• 公司于1989年在香港成立，目前拥有多个知名品牌，业务遍及全球多个国家和地区。
• 公司近年来业绩表现稳健，并积极拓展海外市场，加大对数字化技术的投入，为未来发展奠定了坚实基础。

本新闻稿仅供参考，不构成任何投资建议。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.